Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 570

1.

Validation of Teleconference-based Goniometry for Measuring Elbow Joint Range of Motion.

Dent PA Jr, Wilke B, Terkonda S, Luther I, Shi GG.

Cureus. 2020 Feb 9;12(2):e6925. doi: 10.7759/cureus.6925.

2.

The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.

Roberts JL, Poklepovic A, Booth L, Dent P.

Cell Signal. 2020 Feb 19;70:109573. doi: 10.1016/j.cellsig.2020.109573. [Epub ahead of print]

PMID:
32087304
3.

Fingolimod Augments Monomethylfumarate Killing of GBM Cells.

Dent P, Booth L, Roberts JL, Poklepovic A, Hancock JF.

Front Oncol. 2020 Jan 28;10:22. doi: 10.3389/fonc.2020.00022. eCollection 2020.

4.

(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.

Dent P, Booth L, Roberts JL, Poklepovic A, Hancock JF.

J Cell Physiol. 2020 Jan 27. doi: 10.1002/jcp.29580. [Epub ahead of print]

PMID:
31985048
5.

GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.

Booth L, Roberts JL, West C, Von Hoff D, Dent P.

J Cell Physiol. 2020 Jan 17. doi: 10.1002/jcp.29464. [Epub ahead of print]

PMID:
31951027
6.

Ataxia Telangiectasia Diagnosed on Newborn Screening-Case Cohort of 5 Years' Experience.

Mandola AB, Reid B, Sirror R, Brager R, Dent P, Chakroborty P, Bulman DE, Roifman CM.

Front Immunol. 2019 Dec 20;10:2940. doi: 10.3389/fimmu.2019.02940. eCollection 2019.

7.

Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.

Dent P, Booth L, Poklepovic A, Martinez J, Hoff DV, Hancock JF.

J Cell Physiol. 2020 Jan 8. doi: 10.1002/jcp.29443. [Epub ahead of print]

PMID:
31912905
8.

Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].

Dent P, Booth L, Poklepovic A, Hoff DV, Hancock JF.

Cell Signal. 2020 Jan 3;68:109525. doi: 10.1016/j.cellsig.2020.109525. [Epub ahead of print]

9.

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.

Dent P, Booth L, Poklepovic A.

Immunometabolism. 2020;2(1). pii: e200002. doi: 10.20900/immunometab20200002. Epub 2019 Dec 4.

PMID:
31885880
10.

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer.

Dent P.

Expert Opin Investig Drugs. 2019 Dec;28(12):1095-1100. doi: 10.1080/13543784.2019.1694661. Epub 2019 Nov 29. Review.

PMID:
31783714
11.

Not the comfy chair! Cancer drugs that act against multiple active sites.

Booth L, Poklepovic A, Dent P.

Expert Opin Ther Targets. 2019 Nov;23(11):893-901. doi: 10.1080/14728222.2019.1691526. Epub 2019 Nov 14. Review.

PMID:
31709855
12.

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib.

Booth LA, Roberts JL, Dent P.

Semin Cancer Biol. 2019 Oct 20. pii: S1044-579X(19)30024-0. doi: 10.1016/j.semcancer.2019.10.013. [Epub ahead of print] Review.

PMID:
31644944
13.

Signaling alterations caused by drugs and autophagy.

Dent P, Booth L, Poklepovic A, Hancock JF.

Cell Signal. 2019 Dec;64:109416. doi: 10.1016/j.cellsig.2019.109416. Epub 2019 Sep 11. Review.

PMID:
31520735
14.

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2019 Aug 20;10(49):5120-5122. doi: 10.18632/oncotarget.27162. eCollection 2019 Aug 20.

15.

Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs.

Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P.

Mol Cancer Ther. 2019 Sep;18(9):1669. doi: 10.1158/1535-7163.MCT-19-0666. No abstract available.

PMID:
31481480
16.

Coupled Turbidity and Spectroscopy Problems: A Simple Algorithm for Volumetric Analysis of Optically Thin or Dilute, In Vitro Bacterial Cultures in Various Media.

Ortiz S, McDonough RT, Dent P, Goodisman J, Chaiken J.

Appl Spectrosc. 2020 Mar;74(3):261-274. doi: 10.1177/0003702819872754.

PMID:
31397583
17.

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.

Booth L, Roberts JL, Poklepovic A, Dent P.

Front Oncol. 2019 Jul 18;9:650. doi: 10.3389/fonc.2019.00650. eCollection 2019.

18.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.

Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC, Roberts JD, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P, Poklepovic AS.

Am J Clin Oncol. 2019 Aug;42(8):649-654. doi: 10.1097/COC.0000000000000567.

PMID:
31305287
19.

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.

Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF.

Oncogene. 2019 Jul;38(30):5890-5904. doi: 10.1038/s41388-019-0849-8. Epub 2019 Jun 28.

PMID:
31253872
20.

Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1180. doi: 10.1158/1535-7163.MCT-19-0470. No abstract available.

21.

Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.

Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S.

Mol Cancer Ther. 2019 Jun;18(6):1179. doi: 10.1158/1535-7163.MCT-19-0469. No abstract available.

22.

Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272].

Dasmahapatra G, Nguyen TK, Dent P, Grant S.

Leuk Res. 2019 Jul;82:46-47. doi: 10.1016/j.leukres.2019.03.002. Epub 2019 May 10. No abstract available.

PMID:
31079870
23.

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncol Signal. 2018 Jun;1(1):19-30. doi: 10.1016/j.onsig.2017.07.001. Epub 2017 Aug 16.

24.

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.

Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, Hancock JF, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):700-710. doi: 10.1080/15384047.2018.1551747. Epub 2018 Dec 20.

25.

Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition.

Booth L, Roberts JL, Spiegel S, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):597-607. doi: 10.1080/15384047.2018.1538616. Epub 2018 Nov 2.

26.

Neratinib augments the lethality of [regorafenib + sildenafil].

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P.

J Cell Physiol. 2019 Apr;234(4):4874-4887. doi: 10.1002/jcp.27276. Epub 2018 Sep 10.

27.

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(2):157-168. doi: 10.1080/15384047.2018.1507665. Epub 2018 Sep 5.

28.

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(1):109-121. doi: 10.1080/15384047.2018.1507258. Epub 2018 Aug 24.

29.

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.

Booth L, Roberts J, Poklepovic A, Dent P.

Cancer Biol Ther. 2018;19(9):786-796. doi: 10.1080/15384047.2018.1472189. Epub 2018 Jul 19.

30.

Valproate augments Niraparib killing of tumor cells.

Booth L, Roberts JL, Rais R, Poklepovic A, Dent P.

Cancer Biol Ther. 2018;19(9):797-808. doi: 10.1080/15384047.2018.1472190. Epub 2018 Aug 1.

31.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

32.

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P.

Adv Cancer Res. 2018;137:1-15. doi: 10.1016/bs.acr.2017.11.004. Epub 2018 Jan 3. Review.

33.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

34.

TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition.

Lima S, Takabe K, Newton J, Saurabh K, Young MM, Leopoldino AM, Hait NC, Roberts JL, Wang HG, Dent P, Milstien S, Booth L, Spiegel S.

Autophagy. 2018;14(6):942-957. doi: 10.1080/15548627.2018.1429875. Epub 2018 Mar 11.

35.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

36.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

37.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27. Erratum in: Oncotarget. 2019 Aug 20;10(49):5120-5122.

38.

HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P.

Oncotarget. 2017 May 17;8(47):83155-83170. doi: 10.18632/oncotarget.17950. eCollection 2017 Oct 10.

39.

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.

Booth L, Roberts JL, Poklepovic A, Dent P.

Cancer Biol Ther. 2017 Sep 2;18(9):705-714. doi: 10.1080/15384047.2017.1362511.

40.

Litigation in thyroid surgery in England.

Dent PC, Bagnall NM.

Br J Hosp Med (Lond). 2017 Apr 2;78(4):213-218. doi: 10.12968/hmed.2017.78.4.213.

PMID:
28398893
41.

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.

Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P.

Oncotarget. 2017 Mar 7;8(10):16367-16386. doi: 10.18632/oncotarget.14829.

42.

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].

Booth L, Roberts JL, Poklepovic A, Dent P.

Oncotarget. 2017 Feb 21;8(8):13464-13475. doi: 10.18632/oncotarget.14562.

43.

AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins.

Booth L, Roberts JL, Ecroyd H, Reid SP, Proniuk S, Zukiwski A, Jacob A, Damonte E, Tuñón MJ, Dent P.

J Clin Cell Immunol. 2016 Oct;7(5). pii: 454. Epub 2016 Sep 16. No abstract available.

44.

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.

Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P.

Oncotarget. 2017 Jan 3;8(1):1449-1468. doi: 10.18632/oncotarget.13640.

45.

Primary Immune Deficiencies in the Adult: A Previously Underrecognized Common Condition.

Rosenberg E, Dent PB, Denburg JA.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1101-1107. doi: 10.1016/j.jaip.2016.09.004. Review.

PMID:
27836059
46.

Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.

Booth L, Albers T, Roberts JL, Tavallai M, Poklepovic A, Lebedyeva IO, Dent P.

Oncotarget. 2016 Jun 28;7(26):40398-40417. doi: 10.18632/oncotarget.9752.

47.

Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.

Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P.

J Biol Chem. 2016 Sep 23;291(39):20823. doi: 10.1074/jbc.A116.803444. No abstract available.

48.

Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway.

Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S.

J Biol Chem. 2016 Aug 19;291(34):17535. doi: 10.1074/jbc.A109.095208. No abstract available.

49.

Melanoma Differentiation-associated Gene 7/IL-24 Exerts Cytotoxic Effects by Altering the Alternative Splicing of Bcl-x Pre-mRNA via the SRC/PKCδ Signaling Axis.

Shapiro BA, Vu NT, Shultz MD, Shultz JC, Mietla JA, Gouda MM, Yacoub A, Dent P, Fisher PB, Park MA, Chalfant CE.

J Biol Chem. 2016 Oct 7;291(41):21669-21681. Epub 2016 Aug 12.

50.

Repurposing Tecfidera for cancer.

Booth L, Malkin M, Dent P.

Aging (Albany NY). 2016 Jul;8(7):1289-90. doi: 10.18632/aging.101001. No abstract available.

Supplemental Content

Support Center